Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Cholestanol accelerates α-synuclein aggregation and spreading by activating asparagine endopeptidase
Ting Yu, … , Liam Chen, Zhentao Zhang
Ting Yu, … , Liam Chen, Zhentao Zhang
Published November 8, 2023
Citation Information: JCI Insight. 2023;8(21):e165841. https://doi.org/10.1172/jci.insight.165841.
View: Text | PDF
Research Article Neuroscience

Cholestanol accelerates α-synuclein aggregation and spreading by activating asparagine endopeptidase

  • Text
  • PDF
Abstract

Cerebrotendinous xanthomatosis (CTX), an autosomal recessive disorder characterized by high levels of cholestanol in the blood and accumulation of cholestanol in multiple tissues, especially the brain, often presents in parkinsonism. However, it remains unknown whether cholestanol plays a role in the pathogenesis of sporadic Parkinson’s disease (PD). Here, we show that the levels of serum cholestanol in patients with sporadic PD are higher than those in control participants. Cholestanol activates the protease asparagine endopeptidase (AEP) and induces the fragmentation of α-synuclein (α-syn) and facilitates its aggregation. Furthermore, cholestanol promotes the spreading of α-syn pathology in a mouse model induced by intrastriatal injection of α-syn fibrils. KO of AEP or administration of an AEP inhibitor ameliorates α-syn pathology, degeneration of the nigrostriatal dopaminergic pathway, and PD-like motor symptoms. These results not only indicate that cholestanol contributes to the aggregation and spreading of α-syn by activating AEP but also reveal an opportunity for treating PD with AEP inhibitors.

Authors

Ting Yu, Shuke Nie, Lihong Bu, Miao Liu, Juanfeng He, Xuan Niu, Hongyan Feng, Jifeng Guo, Beisha Tang, Zhaohui Zhang, Keqiang Ye, Haiqiang Jiang, Liam Chen, Zhentao Zhang

×

Figure 1

Cholestanol induces cell injury by activating the C/EBPβ/AEP pathway.

Options: View larger image (or click on image) Download as PowerPoint
Cholestanol induces cell injury by activating the C/EBPβ/AEP pathway.
(A...
(A) Viability of SH-SY5Y cells exposed to vehicle (0 μM) or cholestanol (5, 10, 20, or 40 μM) for 24 hours (n = 5 independent experiments). (B) The levels of ROS after exposure to cholestanol (5 μM) for 24 hours. (C) mRNA levels of LGMN (n = 4 independent experiments). (D) AEP activity assay (n = 6 independent experiments). (E) Western blot analysis of C/EBPβ, p-C/EBPβ, AEP, AEP-generated α-syn N103 fragment, p-α-syn, and total α-syn in cholestanol-treated SH-SY5Y cells (n = 5). (F) Western blots showing the effect of cholestanol (20 μM) on AEP, AEP-generated α-syn N103 fragment, p-α-syn, and total α-syn in SH-SY5Y cells transfected with sh-LGMN (n = 5). (G) Western blots showing the effect of cholestanol (20 μM) on the AEP-generated α-syn N103 fragment, p-α-syn, and total α-syn in SH-SY5Y cells pretreated with CP11 (2 μM) (n = 5). Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. Student’s t test was used in C; 1-way ANOVA with Tukey’s multiple comparison was used in A and D–G. AFU, arbitrary fluorescence unit; NC, negative control.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts